Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides
Objective: Patients included in MAINRITSAN2 trial received either an individually tailored or a fixed-schedule therapy with rituximab as maintenance treatment of antineutrophil cytoplasm antibody associated vasculitides. The aim of this study was to compare the real-world costs of both arms. Meth...
Saved in:
| Main Authors: | Ana Belén Guisado-Gil, Marina Muñoz-Burgos, Ana Ortega-Eslava, Francisco Javier García-Hernández, Bernardo Santos-Ramos |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11287.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recurrent strokes as the sole manifestation of antineutrophil cytoplasmic antibody associated vasculitis in a patientwith panuveitis: a case report
by: Hadeel Seraj, et al.
Published: (2025-02-01) -
INTERLEUKIN-23 IN PATIENTS WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED SYSTEMIC VASCULITIDES: THE AUTHORS’ RESULTS AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2015-10-01) -
International guidelines for the management ofANCA-associated systemic vasculitides
by: T. V. Beketova
Published: (2019-03-01) -
Rituximab versus azathioprine in maintenance therapy of patients with granulomatosis with polyangiitis
by: Samira Alesaeidi, et al.
Published: (2025-06-01) -
Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study
by: Ekbote Gayatri, et al.
Published: (2019-01-01)